MyMD Pharmaceuticals, Inc. (MYMD)
NASDAQ: MYMD · IEX Real-Time Price · USD
1.790
+0.010 (0.56%)
Jul 22, 2024, 9:58 AM EDT - Market open
MyMD Pharmaceuticals Employees
MyMD Pharmaceuticals had 6 employees as of December 31, 2023. The number of employees decreased by 3 or -33.33% compared to the previous year.
Employees
6
Change (1Y)
-3
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$2,925,001
Market Cap
4.27M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 6 | -3 | -33.33% |
| Dec 31, 2022 | 9 | 0 | - |
| Dec 31, 2021 | 9 | 3 | 50.00% |
| Dec 31, 2020 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| OpGen | 100 |
| Genetic Technologies | 60 |
| Genprex | 26 |
| Trevena | 23 |
| Sonnet BioTherapeutics Holdings | 12 |
| CERo Therapeutics Holdings | 9 |
| Palisade Bio | 9 |
| Allarity Therapeutics | 6 |
MYMD News
- 5 weeks ago - MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer - Business Wire
- 2 months ago - MyMD Pharmaceuticals Secures Strategic Investments - Business Wire
- 2 months ago - PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease - Business Wire
- 4 months ago - MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing - Business Wire
- 5 months ago - MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing - Business Wire
- 7 months ago - MyMD Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment Drug - Accesswire
- 8 months ago - MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis - Business Wire
- 9 months ago - MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain - Business Wire